Saturday, June 4, 2021

Medivation: The Most Promising Upcoming Prostate Cancer Treatment

Prostate cancer is the most common form of cancer among men, and two new companies in Medivation and Johnson & Johnson are leading the charge with their experimental new treatments. These two will highlight their findings at The American Society of Clinical Oncology (ASCO), a meeting which has quickly become one of the most important events of the year. From an investment standpoint, the momentum in cancer drug stocks has emerged well ahead of the May 18th deadline as investors pile on the bets on whom will reign supreme. This meeting will highlight some of the world’s most promising cancer drug stocks, and atop the list are two that are currently going head-to-head for the crowned king of prostate cancer treatments.  These new experimental drugs are being fostered by Medivation’s (NASDAQ:MDVN) MDV-3100, and Johnson and Johnson’s (NYSE:JNJ) abiraterone, whom both are set to present critical phase III data results at any time prior or during the meeting.

Of the two, the highest potential and most promising data from early to mid-stage trials belongs to Medivation, as the company is on the verge of becoming one of the most sought after oncology companies, whose product could be a medical breakthrough by all means when comparing its results to currently available options.These developments have led to many analysts upgrading the company’s short-term price target to well beyond $24 a share.

The profit potential for anyone entering this target market is truly staggering. Development of new therapies and drugs for prostate cancer is likely to supplement, rather substitute the prevailing drugs or therapies, such as chemotherapy, radiation therapy, hormonal therapy and surgery, and propel sales in global prostate cancer therapeutics market to $4.8 billion by 2015. Growth in prostate cancer therapies can be attributed to the increase in number of prostate cancer incidences in men aged more than 60 years. Given the longevity of an average individual, and the rapidly aging world population, the risk of prostate cancer stands tall. Statistics reveal that an estimated 1.4 million new invasive cancer cases diagnosed in the US alone in the year 2008.

Comparing Medivation’s MDV-3100 vs. Johnson & Johnson’s abiraterone

Men diagnosed with advanced prostate cancer but not yet treated with chemotherapy lived a median 420 days with MDV-3100 before their disease progressed again, according to a Phase I/II trial with partner Astellas Pharma Inc. That compares favorably with Johnson & Johnson’s experimental prostate cancer drug abiraterone, which in a Phase III trial reported in October showed patients lived 234 days before the disease progressed.

“Abiraterone has the most robust data seen to date,” said Medivation CEO David Hung, “and we’re well-positioned right behind them.”

Medivation and Astellas have four additional trials planned or under way for MDV-3100: two Phase III studies with a total of 2,900 patients, and two mid-stage trials.

A strong showing in those trials could help Medivation’s drug line up as the first in a line of treatments to combat prostate cancer that has spread to other parts of the body but hasn’t yet faced chemotherapy, Hung said.

“The pre-chemo opportunity is many times larger than the post-chemo opportunity,” Hung said, since there are more men diagnosed with prostate cancer who haven’t gone through chemotherapy and they live longer.

According to Wall Street analyst, Larry Smith, “MDV 3100 has the potential to be used in every stage of prostate cancer from first line now treated with the hormonal drug, Abbott’s (NYSE:ABT) Lupron through to fifth line patients in the final stages of the disease who are refractory to the chemotherapy drug, Sanofi-Aventis’ (NYSE:SNY) Taxoterre. Its mode of action should also allow it to be used in combination with abiraterone, Dendreon’s (NASDAQ:DNDN) Provenge, LHRH agents like Lupron and chemotherapy. Because it does not require concomitant use of a steroid, it might have a safety advantage over abiraterone. If most things go right in the clinical trials, this drug could be a multi-billion commercial opportunity for Medivation and its partner, the Japanese company Astellas (PINK:ALPMY).”

From the above comparison, it is noticeable that MDV-3100 compares very favorably to abiraterone in most of the five important measures of effect on tumors.

Medivation also maintains a healthy balance sheet, with nearly $207.8 million cash and equivalents, which should see it fund operations well beyond 2012.

Upcoming FDA Catalysts

The company expects to report top-line results on Dimebon from its phase III HORIZON (Huntington disease) study in the first half of 2011. Meanwhile, Medivation continues to evaluate Dimebon in the CONCERT study, which is being conducted with patients suffering from mild-to-moderate Alzheimer’s. Robust results from this study along with data from an earlier study could be enough to support Dimebon’s approval for mild-to-moderate Alzheimer’s disease. Results from the CONCERT study are expected in the first half of 2012.

Medivation and partner Astellas finished enrolling patients for the phase III AFFIRM study (advanced prostate cancer) in Nov 2010. The companies initiated another phase III study (PREVAIL), which is being conducted in chemotherapy-naïve advanced prostate cancer patients. The initiation of this study triggered a $10 million milestone payment from Astellas.

Medivation and Astellas also intend to commence two new studies with MDV3100 in the first half of 2011. While one trial will be a head-to-head phase II study between MDV3100 and AstraZeneca’s (AZN) Casodex (bicalutamide), the other study (phase II) will be conducted in hormone-naïve patients. Top-line results from AFFIRM should be out in 2012. However, results could be presented in 2011 itself if an interim analysis is conducted. All information via Zack’s Investment Research.

Analyst Recommendations

  • 2/16/11 – Global Hunter Securities maintains a ‘Buy’ on Medivation, raises PT from $19 to $24
  • 11/30/10 – Wedbush assumes coverage on Medivation with a Outperform. PT $25

Technical Analysis

The target for Medivation is set to $25 based on the Ascending Triangle pattern that has formed over the last three months, which is confirmed by the decreasing volume as accumulation by institutions and mutual funds is present before the breakout. The relative strength index (RSI) has also broken out of the symmetrical triangle formation, thus heavy buying pressure can be expected as money flows back into the equity in anticipation of upcoming catalysts.

A ‘golden cross’, whereby the 50-day moving average and the 200-day moving average cross in a positive manner has occurred, and often spells higher prices moving forward for the equity. There is strong support at the $16.23 (50-day MA) level with light resistance at the $17.50 level which should be broken within the next few trading sessions. Both MACD divergence and full stochastic look eerily similar to early December and February, when the stock saw strong gains of well beyond 30% in a matter of two weeks respectively.

The point & figure chart also forecasts a move towards the $22.50 level in the short-term, as the bullish behaviour is expected to continue.

Disclosure: Long MDVN

[[T_F]]Data Leak Prevention - Data Security Solutions - Information Theft Protection, Detection and Prevention Software Productstracefusion_signature=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[[T_F]]

Initially starting in the film industry, during the past three years, Edoardo has studied the financial markets along with a few of his closest friends and began writing as an editor for one of the largest newspaper publications in his city. This offered him the opportunity to meet new co-workers and lifelong friends which ultimately led to him into moving onto helping form His portfolio style often follow the biotech field, with a mixture of long and short ideas, and has been quoted in a number of well known online financial publications. He prides in investigative research through the use of SEC filings, FDA calendars and mainstream media in order to bring about the most interesting stories to life.
Edoardo Lopezpineda
Edoardo Lopezpineda

Tags: , ,

| More

Related Articles

Leave a Reply

Back to Top

Social Media Profiles

  • Facebook
  • Twitter
  • LinkedIn


  • Toronto Web Design
  • Market Guru
  • Klinkoo Innovative Search Engine
  • Credit Land
  • Stock Reads
  • Small Cap Stocks
  • TRADING THE ODDS - Stock market timing and quantitative analysis
  • Economics as Classical Mechanics
  • Matrix Markets
  • Mylant’s Money Blog
  • VIX and More
  • Part-time Pennystock Trader
  • Penny Stocks Classroom



The New York Times logo CNN logo ABC logo CNBC logo